OS Therapies Incorporated
OSTX
$1.79
$0.084.68%
AMEX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.14% | 33.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 74.25% | 42.18% | |||
| Operating Income | -74.25% | -42.18% | |||
| Income Before Tax | -95.67% | -51.64% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -95.67% | -51.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -95.67% | -51.64% | |||
| EBIT | -74.25% | -42.18% | |||
| EBITDA | -75.63% | -42.92% | |||
| EPS Basic | -79.42% | -19.21% | |||
| Normalized Basic EPS | -79.55% | -19.13% | |||
| EPS Diluted | -79.42% | -19.21% | |||
| Normalized Diluted EPS | -79.55% | -19.13% | |||
| Average Basic Shares Outstanding | 9.03% | 27.24% | |||
| Average Diluted Shares Outstanding | 9.03% | 27.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||